Figure 2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors

<p>Mean (± SD) serum concentration of IPH5201 across dose cohorts and treatment. Data are shown based on the PK analysis set, defined as patients who received ≥1 dose of IPH5201 or durvalumab (durva) and provided ≥1 quantifiable posttreatment sample. Vertical lines represent the geometric ± SD...

Бүрэн тодорхойлолт

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолч:	John Powderly (15026168) (author)
Бусад зохиолчид:	Martina Imbimbo (15118007) (author), Antoine Italiano (15054013) (author), Patricia Martin-Romano (22288066) (author), Meredith McKean (20432950) (author), Teresa Macarulla (15050234) (author), Eduardo Castañón Alvarez (22288069) (author), Benedito A. Carneiro (15925723) (author), Raymond Mager (17316025) (author), Vicky Barnhart (22288072) (author), Steven Eck (22288075) (author), Elina Murtomaki (19849066) (author), Arsène-Bienvenu Loembé (22288078) (author), Yun He (22288081) (author), Zachary A. Cooper (15054236) (author), Eric Tu (22288084) (author), Chunling Fan (22288087) (author), Agnes Boyer Chamard (22288090) (author), Carine Paturel (22288093) (author), Paula G. Fraenkel (22288096) (author), Antoine Hollebecque (15010338) (author)
Хэвлэсэн:	2025
Нөхцлүүд:	Cancer Cancer Biology Immuno-oncology Clinical Research and Trials Antibody Immunotherapy Combination Immunotherapy Immunotherapy Oncogenes & Tumor Suppressors PD-1 Phase I Clinical Trials
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Figure 2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors

Ижил төстэй зүйлс